BerGenBio

Regulatory Filings • Apr 9, 2019

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

Bergen, Norway, April 09 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company focused on developing a pipeline of first-in-class

drug candidates targeting AXL kinase to treat aggressive diseases including

immune-evasive and therapy resistant cancers, announces that Richard Godfrey,

BerGenBio's Chief Executive Officer, will present an overview of the Company at

the H.C. Wainwright Global Life Sciences Conference today, April 9, 2019.

Date: Tuesday, April 9, 2019

Time: 09:10 AM BST

Location: JW Marriott Grosvenor House, London, UK

The presentation slides will be available on www.bergenbio.com in the investor

section at time of presentation.

- END -

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad Phase II oncology clinical development

programme focussed on combination and single agent therapy in lung cancer and

leukaemia. A first-in-class functional blocking anti-AXL antibody is undergoing

Phase I clinical testing. In parallel, BerGenBio is developing a companion

diagnostic test to identify those patient populations most likely to benefit

from bemcentinib: this is expected to facilitate more efficient registration

trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Nicholas Brown, Carina Jurs, Consilium Strategic

Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.